申请人:John Wyeth & Brother, Limited
公开号:US05382583A1
公开(公告)日:1995-01-17
Piperazine derivatives of formula: ##STR1## and their pharmaceutically acceptable acid addition salts are disclosed. In the formula, n is 1 or 2; R and R.sup.5 are hydrogen or lower alkyl, R.sup.1 is substituted or unsubstituted aryl or a heteroaromatic radical; R.sup.3 is substituted or unsubstituted aryl or substituted or unsubstituted arylalkyl; R.sup.9 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl or substituted or unsubstituted arylalkyl with the proviso that when R.sup.9 is hydrogen, alkyl, or arylalkyl, R.sup.5 is other than a tertiary alkyl group. The compounds of this invention are useful 5-HT.sub.1A antagonists for the treatment of CNS disorders such as anxiety.
本发明公开了式子如下的哌嗪衍生物及其药学上可接受的酸盐。在公式中,n为1或2;R和R.sup.5为氢或低级烷基,R.sup.1为取代或未取代的芳基或杂环芳基基团;R.sup.3为取代或未取代的芳基或取代或未取代的芳基烷基;R.sup.9为氢、烷基、环烷基、环烷基烷基或取代或未取代的芳基烷基,但当R.sup.9为氢、烷基或芳基烷基时,R.sup.5不是三级烷基。本发明的化合物可用作5-HT.sub.1A拮抗剂,用于治疗中枢神经系统疾病,如焦虑症。